What’s ‘BerkshAmazMorgan’ Really Capable Of?

Posted by Howard Deutsch on Tue, Feb 20, 2018

Bill Coyle, Paul Darling and Pratap Khedkar co-authored this post with Howard Deutsch.

This is the first post in a two-part series on the recently announced Berkshire Hathaway/Amazon/JPMorgan Chase healthcare venture. 

Look! Out in the distance! What’s that creature that’s destroying everything in its path? Why, it’s the scariest three-headed monster this side of Cerberus! It’s… it’s… it’s BerkshAmazMorgan! Will any of us be safe from this dreaded, rampaging beast?


>
Read More

Are You Ready to Deliver an AI-Enabled Customer Experience?

Posted by Pratap Khedkar on Tue, Feb 13, 2018

Saby Mitra co-authored this blog post with Pratap Khedkar.

When it comes to cutting-edge analytics initiatives, you’re probably more inclined to think of companies like Amazon and Netflix, which have become synonymous with the savvy use of analytics to gauge customer affinity and deliver recommendations. But pharma companies are—or could be—well equipped to leverage data and analytics to deliver an even better informed and better targeted customer experience.


>
Read More

Reinvent Your Commercial Strategy With an ‘Outside-In’ Approach

Posted by ZS Editors on Fri, Feb 09, 2018

It used to be that pharma companies could start with the new drugs—their inventions—when planning their go-to-market strategies, but that inside-out approach doesn’t work in an increasingly customer-centric marketplace. It’s time for drug manufacturers to transition from their inside-out business models to an outside-in approach, realigning their structures and rethinking their research and resources to better assess and adapt to the changing healthcare ecosystem, and to better meet their stakeholders’ evolving needs.


>
Read More

Winning Isn’t Easy: What Biopharma Companies Can Do to Find Success in a Crowded Marketplace

Posted by Ross Shahinian on Wed, Feb 07, 2018

Christina Corridon co-wrote this blog post with Ross Shahinian.

In 2017, there were 46 novel drug approvals in the U.S., according to the FDA. However, the majority (67%) of these drug approvals represent later-to-market entrants that will be vying for share in an increasingly competitive landscape. For example, take Verzenio, Lilly’s CDK-inhibitor for HR-positive breast cancer, which was third to market after Pfizer’s Ibrance and Novartis’s Kisqali. Or Steglatro, the Merck and Pfizer fourth-to-market SGLT-2 drug, which came in after Invokana, Farxiga and Jardiance.


>
Read More

Five Steps to Address the Pain Points of Co-Pay Accumulator Programs

Posted by Howard Deutsch on Wed, Jan 31, 2018

In the cat-and-mouse co-pay card game, payers have made their next move. Pharmacy benefit managers have been promoting “co-pay accumulator” programs to plan sponsors as a way to reduce specialty drug spending. Left alone, these programs will result in confused patients who are less likely to adhere to their medications, and high costs for pharmaceutical manufacturers. Pharma companies need to respond.


>
Read More